1. Home
  2. RFL vs ICCC Comparison

RFL vs ICCC Comparison

Compare RFL & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.49

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$6.53

Market Cap

55.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
ICCC
Founded
2017
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
55.5M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
RFL
ICCC
Price
$1.49
$6.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
58.8K
13.2K
Earning Date
03-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
28.28
65.33
EPS
N/A
0.20
Revenue
$917,000.00
$26,493,169.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$32.00
Revenue Growth
43.96
51.64
52 Week Low
$1.12
$4.32
52 Week High
$3.19
$7.60

Technical Indicators

Market Signals
Indicator
RFL
ICCC
Relative Strength Index (RSI) 76.62 53.42
Support Level $1.41 $5.72
Resistance Level $1.60 $6.91
Average True Range (ATR) 0.07 0.23
MACD 0.02 -0.00
Stochastic Oscillator 75.61 57.43

Price Performance

Historical Comparison
RFL
ICCC

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: